Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Accumulated Expenses (2024 - 2025)

Historic Accumulated Expenses for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to $12.9 million.

  • Prelude Therapeutics' Accumulated Expenses fell 477.94% to $12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.9 million, marking a year-over-year decrease of 477.94%. This contributed to the annual value of $15.2 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Prelude Therapeutics' Accumulated Expenses is $12.9 million, which was down 477.94% from $13.2 million recorded in Q2 2025.
  • Prelude Therapeutics' 5-year Accumulated Expenses high stood at $15.2 million for Q4 2024, and its period low was $10.1 million during Q1 2024.